EX-99.1 2 a18-17316_1ex99d1.htm EX-99.1

Exhibit 99.1

 

News Release

 

Abbott Reports Second-Quarter 2018 Results

 

·                 Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40

·                 Second-quarter organic sales growth of 8.0 percent

·                 Second-quarter adjusted EPS from continuing operations of $0.73, above previous guidance range

·                 Raises full-year 2018 outlook

 

ABBOTT PARK, Ill., July 18, 2018 — Abbott today announced financial results for the second quarter ended June 30, 2018.

 

·                  Second-quarter worldwide sales of $7.8 billion increased 17.0 percent on a reported basis and 8.0 percent on an organic* basis.

·                  Reported diluted EPS from continuing operations under GAAP was $0.40 in the second quarter.

·                  Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.73, above Abbott’s previous guidance range.

·                  Abbott is raising its full-year 2018 EPS guidance range, which continues to reflect strong double-digit growth. Abbott projects full-year diluted EPS from continuing operations on a GAAP basis of $1.34 to $1.40. Projected full-year adjusted diluted EPS from continuing operations is now $2.85 to $2.91.

·                  In May, Abbott received approval from the U.S. FDA for XIENCE SierraTM, the newest generation of its gold-standard coronary stent system, which offers design and technology advances to provide an easier implant and greater ability to treat complex blockages. During the second quarter, XIENCE Sierra also received national reimbursement in Japan to treat people with coronary artery disease.

·                  In May, Abbott announced U.S. FDA clearance of AdvisorTM HD Grid Mapping Catheter, Sensor EnabledTM, which creates highly detailed maps of the heart and expands Abbott’s leading electrophysiology product portfolio.

·                  In July, Abbott received U.S. FDA approval for a next-generation version of its leading MitraClip® heart valve repair device. This new version includes design advancements that simplify the minimally invasive procedure and enable more patients to be treated with MitraClip.

 

“All four of our businesses exceeded expectations and contributed to strong growth overall,” said Miles D. White, chairman and chief executive officer, Abbott. “We forecast continued strong performance and are raising our full-year outlook despite recent currency shifts.”

 

—more—

 


* See note on organic growth on the next page.

 



 

SECOND-QUARTER BUSINESS OVERVIEW

 

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business.

 

Organic sales growth:

 

·                  Excludes prior year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter 2017;

·                  Excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on Oct. 3, 2017; and

·                  Excludes the impact of foreign exchange.

 

Following are sales by business segment and commentary for the second quarter and first half 2018:

 

Total Company

($ in millions)

 

 

 

 

 

 

 

 

 

% Change vs. 2Q17

 

 

 

Sales 2Q18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total *

 

2,702

 

5,065

 

7,767

 

14.5

 

18.4

 

17.0

 

3.5

 

10.5

 

8.0

 

Nutrition

 

781

 

1,077

 

1,858

 

1.0

 

12.5

 

7.3

 

1.0

 

10.7

 

6.4

 

Diagnostics

 

652

 

1,221

 

1,873

 

69.1

 

37.6

 

47.2

 

2.2

 

8.5

 

6.6

 

Established Pharmaceuticals

 

 

1,129

 

1,129

 

n/a

 

10.5

 

10.5

 

n/a

 

12.3

 

12.3

 

Medical Devices

 

1,259

 

1,632

 

2,891

 

5.7

 

16.1

 

11.3

 

5.7

 

10.3

 

8.2

 

 


* Total 2018 Abbott sales from continuing operations include Other Sales of $16 million.

 

 

 

 

 

 

 

 

 

% Change vs. 1H17

 

 

 

Sales 1H18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total *

 

5,377

 

9,780

 

15,157

 

14.8

 

18.0

 

16.8

 

4.2

 

9.3

 

7.5

 

Nutrition

 

1,539

 

2,075

 

3,614

 

2.4

 

11.0

 

7.2

 

2.4

 

8.1

 

5.6

 

Diagnostics

 

1,352

 

2,358

 

3,710

 

78.9

 

40.8

 

52.6

 

2.0

 

7.9

 

6.1

 

Established Pharmaceuticals

 

 

2,173

 

2,173

 

n/a

 

10.2

 

10.2

 

n/a

 

9.7

 

9.7

 

Medical Devices

 

2,468

 

3,167

 

5,635

 

6.0

 

18.9

 

12.9

 

6.3

 

11.0

 

8.8

 

 


* Total 2018 Abbott sales from continuing operations include Other Sales of $25 million.

 

n/a = Not Applicable.

 

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Second-quarter 2018 worldwide sales of $7.8 billion increased 17.0 percent on a reported basis. On an organic basis, worldwide sales increased 8.0 percent. Refer to pages 17 and 18 for a reconciliation of adjusted historical revenue.

 

2



 

Nutrition

($ in millions)

 

 

 

 

 

 

 

 

 

% Change vs. 2Q17

 

 

 

Sales 2Q18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

781

 

1,077

 

1,858

 

1.0

 

12.5

 

7.3

 

1.0

 

10.7

 

6.4

 

Pediatric

 

469

 

582

 

1,051

 

2.1

 

10.2

 

6.4

 

2.1

 

8.1

 

5.3

 

Adult

 

312

 

495

 

807

 

(0.7

)

15.2

 

8.5

 

(0.7

)

13.9

 

7.8

 

 

 

 

 

 

 

 

 

 

% Change vs. 1H17

 

 

 

Sales 1H18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

1,539

 

2,075

 

3,614

 

2.4

 

11.0

 

7.2

 

2.4

 

8.1

 

5.6

 

Pediatric

 

917

 

1,128

 

2,045

 

2.9

 

10.3

 

6.8

 

2.9

 

7.2

 

5.2

 

Adult

 

622

 

947

 

1,569

 

1.6

 

11.9

 

7.6

 

1.6

 

9.3

 

6.1

 

 

Worldwide Nutrition sales increased 7.3 percent on a reported basis in the second quarter, including a favorable 0.9 percent effect of foreign exchange, and increased 6.4 percent on an organic basis.

 

Worldwide Pediatric Nutrition sales increased 6.4 percent on a reported basis in the second quarter, including a favorable 1.1 percent effect of foreign exchange, and increased 5.3 percent on an organic basis. International sales increased 10.2 percent on a reported basis, including a favorable 2.1 percent effect of foreign exchange, and increased 8.1 percent on an organic basis. Strong performance in the quarter was led by growth in several countries across Asia, including Greater China, and Latin America.

 

Worldwide Adult Nutrition sales increased 8.5 percent on a reported basis in the second quarter, including a favorable 0.7 percent effect of foreign exchange, and increased 7.8 percent on an organic basis. International sales increased 15.2 percent on a reported basis, including a favorable 1.3 percent effect of foreign exchange, and increased 13.9 percent on an organic basis. Sales performance was led by strong growth of Ensure®, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna®, Abbott’s market-leading diabetes-specific nutrition brand.

 

3



 

Diagnostics

($ in millions)

 

 

 

 

 

 

 

 

 

% Change vs. 2Q17

 

 

 

Sales 2Q18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total *

 

652

 

1,221

 

1,873

 

69.1

 

37.6

 

47.2

 

2.2

 

8.5

 

6.6

 

Core Laboratory

 

248

 

880

 

1,128

 

6.8

 

11.7

 

10.6

 

6.8

 

7.9

 

7.7

 

Molecular

 

38

 

84

 

122

 

(7.3

)

16.6

 

7.9

 

(7.3

)

13.6

 

6.0

 

Point of Care

 

108

 

31

 

139

 

(3.9

)

12.0

 

(0.8

)

(3.9

)

9.7

 

(1.3

)

Rapid Diagnostics *

 

258

 

226

 

484

 

n/m

 

n/m

 

n/m

 

n/m

 

n/m

 

n/m

 

 


* Rapid Diagnostics reflects sales from Alere Inc., which was acquired on Oct. 3, 2017. Organic growth rates above exclude results from the Rapid Diagnostics business.

 

 

 

 

 

 

 

 

 

% Change vs. 1H17

 

 

 

Sales 1H18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total *

 

1,352

 

2,358

 

3,710

 

78.9

 

40.8

 

52.6

 

2.0

 

7.9

 

6.1

 

Core Laboratory

 

476

 

1,671

 

2,147

 

6.2

 

12.7

 

11.2

 

6.2

 

7.3

 

7.0

 

Molecular

 

77

 

163

 

240

 

(10.7

)

17.0

 

6.4

 

(10.7

)

12.6

 

3.7

 

Point of Care

 

218

 

62

 

280

 

(1.7

)

17.3

 

1.9

 

(1.7

)

14.0

 

1.3

 

Rapid Diagnostics *

 

581

 

462

 

1,043

 

n/m

 

n/m

 

n/m

 

n/m

 

n/m

 

n/m

 

 


* Rapid Diagnostics reflects sales from Alere Inc., which was acquired on Oct. 3, 2017. Organic growth rates above exclude results from the Rapid Diagnostics business.

 

n/m = Percent change is not meaningful.

 

Worldwide Diagnostics sales increased 47.2 percent on a reported basis in the second quarter. On an organic basis, sales increased 6.6 percent. Refer to pages 17 and 18 for a reconciliation of adjusted historical revenue.

 

Core Laboratory Diagnostics sales increased 10.6 percent on a reported basis in the second quarter, including a favorable 2.9 percent effect of foreign exchange, and increased 7.7 percent on an organic basis. Growth in the quarter was driven by continued share gains globally.

 

Molecular Diagnostics sales increased 7.9 percent on a reported basis in the second quarter, including a favorable 1.9 percent effect of foreign exchange, and increased 6.0 percent on an organic basis. Worldwide sales were led by strong growth in infectious disease testing, Abbott’s core area of focus in the molecular diagnostics market, which was partially offset by a planned scale down in other testing areas, primarily in the U.S.

 

Point of Care Diagnostics sales decreased 0.8 percent on a reported basis in the second quarter, including a favorable 0.5 percent effect of foreign exchange, and decreased 1.3 percent on an organic basis.

 

Rapid Diagnostics worldwide sales of $484 million were led by infectious disease and cardiometabolic testing.

 

4



 

Established Pharmaceuticals

($ in millions)

 

 

 

 

 

 

 

 

 

% Change vs. 2Q17

 

 

 

Sales 2Q18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

 

1,129

 

1,129

 

n/a

 

10.5

 

10.5

 

n/a

 

12.3

 

12.3

 

Key Emerging Markets

 

 

866

 

866

 

n/a

 

8.4

 

8.4

 

n/a

 

12.0

 

12.0

 

Other

 

 

263

 

263

 

n/a

 

17.9

 

17.9

 

n/a

 

13.6

 

13.6

 

 

 

 

 

 

 

 

 

 

% Change vs. 1H17

 

 

 

Sales 1H18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

 

2,173

 

2,173

 

n/a

 

10.2

 

10.2

 

n/a

 

9.7

 

9.7

 

Key Emerging Markets

 

 

1,659

 

1,659

 

n/a

 

8.6

 

8.6

 

n/a

 

9.5

 

9.5

 

Other

 

 

514

 

514

 

n/a

 

15.9

 

15.9

 

n/a

 

10.1

 

10.1

 

 

Established Pharmaceuticals sales increased 10.5 percent on a reported basis in the second quarter, including an unfavorable 1.8 percent effect of foreign exchange, and increased 12.3 percent on an organic basis.

 

Key Emerging Markets comprise several countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 8.4 percent on a reported basis in the second quarter, including an unfavorable 3.6 percent effect of foreign exchange, and increased 12.0 percent on an organic basis. Sales growth was led by double-digit growth across several geographies, including India and China.

 

5



 

Medical Devices

($ in millions)

 

 

 

 

 

 

 

 

 

% Change vs. 2Q17

 

 

 

Sales 2Q18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

1,259

 

1,632

 

2,891

 

5.7

 

16.1

 

11.3

 

5.7

 

10.3

 

8.2

 

Cardiovascular and Neuromodulation

 

1,147

 

1,274

 

2,421

 

3.4

 

10.7

 

7.1

 

3.4

 

5.4

 

4.4

 

Rhythm Management

 

262

 

281

 

543

 

(3.6

)

0.5

 

(1.5

)

(3.6

)

(4.4

)

(4.0

)

Electrophysiology

 

193

 

235

 

428

 

25.0

 

24.6

 

24.8

 

25.0

 

18.7

 

21.6

 

Heart Failure

 

117

 

46

 

163

 

(5.0

)

27.6

 

2.4

 

(5.0

)

21.4

 

1.0

 

Vascular

 

284

 

466

 

750

 

(3.8

)

7.0

 

2.6

 

(3.8

)

2.0

 

(0.3

)

Structural Heart

 

118

 

197

 

315

 

13.9

 

19.7

 

17.5

 

13.9

 

13.3

 

13.5

 

Neuromodulation

 

173

 

49

 

222

 

7.4

 

5.2

 

6.9

 

7.4

 

0.3

 

5.8

 

Diabetes Care

 

112

 

358

 

470

 

37.6

 

40.5

 

39.8

 

37.6

 

32.4

 

33.6

 

 

 

 

 

 

 

 

 

 

% Change vs. 1H17

 

 

 

Sales 1H18

 

Reported

 

Organic

 

 

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

U.S.

 

Int’l

 

Total

 

Total

 

2,468

 

3,167

 

5,635

 

6.0

 

18.9

 

12.9

 

6.3

 

11.0

 

8.8

 

Cardiovascular and Neuromodulation

 

2,270

 

2,474

 

4,744

 

4.6

 

12.9

 

8.7

 

4.9

 

5.6

 

5.3

 

Rhythm Management

 

526

 

552

 

1,078

 

(1.2

)

4.2

 

1.5

 

(1.2

)

(2.9

)

(2.1

)

Electrophysiology

 

375

 

444

 

819

 

25.4

 

23.4

 

24.3

 

25.4

 

15.7

 

20.1

 

Heart Failure

 

231

 

85

 

316

 

(0.6

)

22.5

 

4.7

 

(0.6

)

14.3

 

2.8

 

Vascular

 

570

 

919

 

1,489

 

(4.9

)

10.2

 

3.9

 

(4.0

)

3.9

 

0.6

 

Structural Heart

 

227

 

381

 

608

 

7.8

 

21.5

 

16.0

 

7.8

 

12.4

 

10.6

 

Neuromodulation

 

341

 

93

 

434

 

14.8

 

8.8

 

13.5

 

14.8

 

1.1

 

11.8

 

Diabetes Care

 

198

 

693

 

891

 

26.5

 

46.9

 

41.8

 

26.5

 

35.5

 

33.3

 

 

Worldwide Medical Devices sales increased 11.3 percent on a reported basis in the second quarter. On an organic basis, sales increased 8.2 percent. Refer to page 18 for a reconciliation of adjusted historical revenue.

 

Cardiovascular and Neuromodulation sales growth in the quarter was led by double-digit growth in Electrophysiology and Structural Heart.

 

In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation as well as share gains from the recent U.S. launch of Abbott’s Confirm RxTM Insertable Cardiac Monitor (ICM), the world’s first and only smartphone-compatible ICM designed to help physicians remotely identify cardiac arrhythmias. In May, Abbott announced U.S. FDA clearance of Advisor HD Grid Mapping Catheter, Sensor Enabled, which creates highly detailed maps of the heart and expands Abbott’s leading electrophysiology product portfolio.

 

In Vascular, during the second quarter, Abbott received approval from the U.S. FDA for XIENCE Sierra, the newest generation of its gold-standard coronary stent system, which offers design and technology advances to provide an easier implant and greater ability to treat complex blockages. During the quarter, XIENCE Sierra also received national reimbursement in Japan to treat people with coronary artery disease.

 

6



 

Growth in Structural Heart was driven by several product areas across Abbott’s broad portfolio, including AMPLATZERTM PFO Occluder and MitraClip, Abbott’s market-leading device for the minimally invasive treatment of mitral regurgitation. In July, Abbott announced U.S. FDA approval for a next-generation version of MitraClip, with an enhanced design that provides even greater precision and accuracy.

 

In Diabetes Care, where sales increased 39.8 percent on a reported basis and 33.6 percent on an organic basis, growth was led by continued rapid market uptake of FreeStyle® Libre, Abbott’s revolutionary sensor-based continuous glucose monitoring (CGM) system, which removes the need for routine fingersticks1 for people with diabetes.

 

7



 

ABBOTT’S FULL-YEAR EARNINGS-PER-SHARE GUIDANCE

 

Abbott projects 2018 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $1.34 to $1.40.

 

Abbott forecasts net specified items for the full year 2018 of approximately $1.51 per share. Specified items include intangible amortization expense, acquisition-related expenses, charges associated with cost reduction initiatives and other expenses.

 

Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $2.85 to $2.91 for the full year 2018.

 

Abbott is issuing third-quarter 2018 guidance for diluted earnings per share from continuing operations under GAAP of $0.32 to $0.34. Abbott forecasts specified items for the third quarter 2018 of $0.41 primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.73 to $0.75 for the third quarter.

 

ABBOTT DECLARES 378TH CONSECUTIVE QUARTERLY DIVIDEND

 

On June 8, 2018, the board of directors of Abbott declared the company’s quarterly dividend of $0.28 per share. Abbott’s cash dividend is payable Aug. 15, 2018, to shareholders of record at the close of business on July 13, 2018.

 

Abbott has increased its dividend payout for 46 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

8



 

About Abbott:

 

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 99,000 people.

 

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

 

Abbott will webcast its live second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.

 

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Lukas Szot, 224-667-2299

 

Abbott Media:

Darcy Ross, 224-667-3655

Elissa Maurer, 224-668-3309

 


1 Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

 

9



 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Second Quarter Ended June 30, 2018 and 2017

(in millions, except per share data)

(unaudited)

 

 

 

2Q18

 

2Q17

 


Change

 

 

 

Net Sales

 

$

7,767

 

$

6,637

 

17.0

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of products sold, excluding amortization expense

 

3,282

 

3,189

 

2.9

 

 

 

Amortization of intangible assets

 

562

 

392

 

43.2

 

 

 

Research and development

 

575

 

520

 

10.5

 

 

 

Selling, general, and administrative

 

2,466

 

2,150

 

14.7

 

 

 

Total Operating Cost and Expenses

 

6,885

 

6,251

 

10.1

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating earnings

 

882

 

386

 

n/m

 

1

)

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

189

 

183

 

2.7

 

 

 

Net foreign exchange (gain)

 

(6

)

(12

)

(50.7

)

 

 

Other (income) expense, net

 

(78

)

(80

)

(3.1

)

1

)

Earnings from Continuing Operations before taxes

 

777

 

295

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense on Earnings from Continuing Operations

 

59

 

25

 

n/m

 

 

 

Earnings from Continuing Operations

 

718

 

270

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings from Discontinued Operations, net of taxes

 

15

 

13

 

19.1

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Earnings

 

$

733

 

$

283

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings from Continuing Operations, excluding Specified Items, as described below

 

$

1,295

 

$

1,096

 

18.1

 

2

)

 

 

 

 

 

 

 

 

 

 

Diluted Earnings per Common Share from:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing Operations

 

$

0.40

 

$

0.15

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Discontinued Operations

 

0.01

 

0.01

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$

0.41

 

$

0.16

 

n/m

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below

 

$

0.73

 

$

0.62

 

17.7

 

2

)

 

 

 

 

 

 

 

 

 

 

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

 

1,769

 

1,749

 

 

 

 

 

 

NOTES:

 

See tables on page 14 for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes on the following page.

 

10



 


1)             Effective January 1, 2018, Abbott adopted Accounting Standards Update 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which resulted in a retrospective reclassification of approximately $40 million of net pension-related income from Operating earnings to Other (income) expense, net for the second quarter of 2017.

 

2)             2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $577 million, or $0.33 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

 

2017 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $826 million, or $0.47 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

 

11



 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Half Ended June 30, 2018 and 2017

(in millions, except per share data)

(unaudited)

 

 

 

1H18

 

1H17

 

%
Change

 

 

 

 

Net Sales

 

$

15,157

 

$

12,972

 

16.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of products sold, excluding amortization expense

 

6,349

 

6,251

 

1.6

 

 

 

 

Amortization of intangible assets

 

1,146

 

914

 

25.4

 

 

 

 

Research and development

 

1,164

 

1,073

 

8.4

 

 

 

 

Selling, general, and administrative

 

5,008

 

4,590

 

9.1

 

 

 

 

Total Operating Cost and Expenses

 

13,667

 

12,828

 

6.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating earnings

 

1,490

 

144

 

n/m

 

1

)

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

388

 

387

 

0.1

 

 

 

 

Net foreign exchange (gain)

 

(9

)

(28

)

(66.5

)

 

 

 

Debt extinguishment costs

 

14

 

 

n/m

 

 

 

 

Other (income) expense, net

 

(111

)

(1,246

)

(91.1

)

1

)

2)

Earnings from Continuing Operations before taxes

 

1,208

 

1,031

 

17.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense on Earnings from Continuing Operations

 

81

 

375

 

(78.4

)

3

)

 

Earnings from Continuing Operations

 

1,127

 

656

 

71.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings from Discontinued Operations, net of taxes

 

24

 

46

 

(49.5

)

4

)

 

 

 

 

 

 

 

 

 

 

 

 

Net Earnings

 

$

1,151

 

$

702

 

63.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings from Continuing Operations, excluding Specified Items, as described below

 

$

2,345

 

$

1,939

 

20.9

 

5

)

 

 

 

 

 

 

 

 

 

 

 

 

Diluted Earnings per Common Share from:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing Operations

 

$

0.63

 

$

0.37

 

70.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discontinued Operations

 

0.01

 

0.03

 

(66.7

)

4

)

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$

0.64

 

$

0.40

 

60.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below

 

$

1.32

 

$

1.11

 

18.9

 

5

)

 

 

 

 

 

 

 

 

 

 

 

 

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

 

1,767

 

1,742

 

 

 

 

 

 

 

NOTES:

 

See tables on page 15 for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes on the following page.

 

12



 


1)             Effective January 1, 2018, Abbott adopted Accounting Standards Update 2017-07, Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which resulted in a retrospective reclassification of approximately $80 million of net pension-related income from Operating earnings to Other (income) expense, net for the first half of 2017.

 

2)             2017 Other (income) expense, net includes a pretax gain of $1.151 billion from the sale of the AMO business.

 

3)             2018 Tax expense on Earnings from Continuing Operations includes the impact of approximately $71 million in excess tax benefits associated with share-based compensation.

 

2017 Tax expense on Earnings from Continuing Operations includes the tax associated with a $1.151 billion pretax gain on the sale of the AMO business.

 

4)             2018 and 2017 Earnings and Diluted Earnings per Common Share from Discontinued Operations, net of taxes primarily relates to a net tax benefit as a result of the resolution of various tax positions from prior years.

 

5)             2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.218 billion, or $0.69 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

 

2017 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.283 billion, or $0.74 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions, partially offset by a gain on the sale of the AMO business.

 

13



 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Second Quarter Ended June 30, 2018 and 2017

(in millions, except per share data)

(unaudited)

 

 

 

2Q18

 

 

 

As
Reported
(GAAP)

 

Specified
Items

 

As
Adjusted

 

% to
Sales

 

 

 

 

 

 

 

 

 

 

 

Intangible Amortization

 

$

562

 

$

(562

)

 

 

 

Gross Margin

 

3,923

 

677

 

$

4,600

 

59.2

%

R&D

 

575

 

(24

)

551

 

7.1

%

SG&A

 

2,466

 

(79

)

2,387

 

30.7

%

Interest expense, net

 

189

 

(2

)

187

 

 

 

Other (income) expense, net

 

(78

)

44

 

(34

)

 

 

Earnings from Continuing Operations before taxes

 

777

 

738

 

1,515

 

 

 

Tax expense on Earnings from Continuing Operations

 

59

 

161

 

220

 

 

 

Earnings from Continuing Operations

 

718

 

577

 

1,295

 

 

 

Diluted Earnings per Share from Continuing Operations

 

$

0.40

 

$

0.33

 

$

0.73

 

 

 

 

Specified items reflect intangible amortization expense of $562 million and other expenses of $176 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 19 for additional details regarding specified items.

 

 

 

2Q17

 

 

 

As
Reported
(GAAP)

 

Specified
Items

 

As
Adjusted

 

% to
Sales

 

 

 

 

 

 

 

 

 

 

 

Intangible Amortization

 

$

392

 

$

(392

)

 

 

 

Gross Margin

 

3,056

 

895

 

$

3,951

 

59.5

%

R&D

 

520

 

(15

)

505

 

7.6

%

SG&A

 

2,150

 

(138

)

2,012

 

30.3

%

Interest expense, net

 

183

 

(2

)

181

 

 

 

Other (income) expense, net

 

(80

)

32

 

(48

)

 

 

Earnings from Continuing Operations before taxes

 

295

 

1,018

 

1,313

 

 

 

Tax expense on Earnings from Continuing Operations

 

25

 

192

 

217

 

 

 

Earnings from Continuing Operations

 

270

 

826

 

1,096

 

 

 

Diluted Earnings per Share from Continuing Operations

 

$

0.15

 

$

0.47

 

$

0.62

 

 

 

 

Note: The As Reported and As Adjusted amounts reflect the impact of adopting the new accounting rules related to the recognition of retirement benefits — See Footnote 1 on page 11 for additional information.

 

Specified items reflect intangible amortization expense of $392 million and other expenses of $626 million, primarily associated with acquisitions, including approximately $430 million of inventory step-up amortization related to St. Jude Medical and other expenses. See page 20 for additional details regarding specified items.

 

14



 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

First Half Ended June 30, 2018 and 2017

(in millions, except per share data)

(unaudited)

 

 

 

1H18

 

 

 

As
Reported
(GAAP)

 

Specified
Items

 

As
Adjusted

 

% to
Sales

 

 

 

 

 

 

 

 

 

 

 

Intangible Amortization

 

$

1,146

 

$

(1,146

)

 

 

 

Gross Margin

 

7,662

 

1,324

 

$

8,986

 

59.3

%

R&D

 

1,164

 

(67

)

1,097

 

7.2

%

SG&A

 

5,008

 

(169

)

4,839

 

31.9

%

Interest expense, net

 

388

 

(2

)

386

 

 

 

Net foreign exchange (gain) loss

 

(9

)

(1

)

(10

)

 

 

Debt extinguishment costs

 

14

 

(14

)

 

 

 

Other (income) expense, net

 

(111

)

42

 

(69

)

 

 

Earnings from Continuing Operations before taxes

 

1,208

 

1,535

 

2,743

 

 

 

Tax expense on Earnings from Continuing Operations

 

81

 

317

 

398

 

 

 

Earnings from Continuing Operations

 

1,127

 

1,218

 

2,345

 

 

 

Diluted Earnings per Share from Continuing Operations

 

$

0.63

 

$

0.69

 

$

1.32

 

 

 

 

Specified items reflect intangible amortization expense of $1.146 billion and other expenses of $389 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 21 for additional details regarding specified items.

 

 

 

1H17

 

 

 

As
Reported
(GAAP)

 

Specified
Items

 

As
Adjusted

 

% to
Sales

 

 

 

 

 

 

 

 

 

 

 

Intangible Amortization

 

$

914

 

$

(914

)

 

 

 

Gross Margin

 

5,807

 

1,879

 

$

7,686

 

59.2

%

R&D

 

1,073

 

(55

)

1,018

 

7.8

%

SG&A

 

4,590

 

(505

)

4,085

 

31.5

%

Interest expense, net

 

387

 

(19

)

368

 

 

 

Other (income) expense, net

 

(1,246

)

1,166

 

(80

)

 

 

Earnings from Continuing Operations before taxes

 

1,031

 

1,292

 

2,323

 

 

 

Tax expense on Earnings from Continuing Operations

 

375

 

9

 

384

 

 

 

Earnings from Continuing Operations

 

656

 

1,283

 

1,939

 

 

 

Diluted Earnings per Share from Continuing Operations

 

$

0.37

 

$

0.74

 

$

1.11

 

 

 

 

Note: The As Reported and As Adjusted amounts reflect the impact of adopting the new accounting rules related to the recognition of retirement benefits — See Footnote 1 on page 13 for additional information.

 

Specified items reflect intangible amortization expense of $914 million and other expenses of $1.529 billion, primarily associated with acquisitions, including approximately $820 million of inventory step-up amortization related to St. Jude Medical, charges related to restructuring actions and other expenses, partially offset by a gain of $1.151 billion from the sale of the AMO business. See page 22 for additional details regarding specified items.

 

15



 

A reconciliation of the second-quarter tax rates for continuing operations for 2018 and 2017 is shown below:

 

 

 

2Q18

 

 

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

 

 

As reported (GAAP)

 

$

777

 

$

59

 

7.7

%

 

 

Specified items

 

738

 

161

 

 

 

 

 

Excluding specified items

 

$

1,515

 

$

220

 

14.5

%

 

 

 

 

 

2Q17

 

 

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

 

 

As reported (GAAP)

 

$

295

 

$

25

 

8.4

%

1

)

Specified items

 

1,018

 

192

 

 

 

 

 

Excluding specified items

 

$

1,313

 

$

217

 

16.5

%

 

 

 


1)             Reported tax rate on a GAAP basis for the second quarter of 2017 includes the impact of approximately $25 million in excess tax benefits associated with share-based compensation.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2018 and 2017 is shown below:

 

 

 

1H18

 

 

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

 

 

As reported (GAAP)

 

$

1,208

 

$

81

 

6.7

%

2

)

Specified items

 

1,535

 

317

 

 

 

 

 

Excluding specified items

 

$

2,743

 

$

398

 

14.5

%

 

 

 

 

 

1H17

 

 

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

 

 

As reported (GAAP)

 

$

1,031

 

$

375

 

36.4

%

3

)

Specified items

 

1,292

 

9

 

 

 

 

 

Excluding specified items

 

$

2,323

 

$

384

 

16.5

%

 

 

 


2)             Reported tax rate on a GAAP basis for 2018 includes the impact of approximately $71 million in excess tax benefits associated with share-based compensation.

 

3)             Reported tax rate on a GAAP basis for 2017 includes the impact of taxes associated with a $1.151 billion pretax gain on the sale of the AMO business.

 

16



 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Adjusted Historical Revenue

Second Quarter Ended June 30, 2018 and 2017

($ in millions) (unaudited)

 

 

 

2Q18

 

2Q17

 

% Change vs. 2Q17

 

 

 

Abbott

 

Rapid

 

Adjusted

 

Abbott

 

 

 

Non-GAAP

 

 

 

Reported

 

Diagnostics

 

Revenue

 

Reported

 

Reported

 

Reported

 

Organic a)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Company

 

7,767

 

(484

)

7,283

 

6,637

 

17.0

 

9.7

 

8.0

 

U.S.

 

2,702

 

(258

)

2,444

 

2,360

 

14.5

 

3.5

 

3.5

 

Int’l

 

5,065

 

(226

)

4,839

 

4,277

 

18.4

 

13.1

 

10.5

 

Total Diagnostics

 

1,873

 

(484

)

1,389

 

1,273

 

47.2

 

9.1

 

6.6

 

U.S.

 

652

 

(258

)

394

 

385

 

69.1

 

2.2

 

2.2

 

Int’l

 

1,221

 

(226

)

995

 

888

 

37.6

 

12.1

 

8.5

 

Rapid Diagnostics

 

484

 

(484

)

 

 

n/m

 

n/m

 

n/m

 

U.S.

 

258

 

(258

)

 

 

n/m

 

n/m

 

n/m

 

Int’l

 

226

 

(226

)

 

 

n/m

 

n/m

 

n/m

 

 


a) In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

17



 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Adjusted Historical Revenue

First Half Ended June 30, 2018 and 2017

($ in millions) (unaudited)

 

 

 

1H18

 

1H17

 

% Change vs. 1H17

 

 

 

Abbott

 

Rapid

 

Adjusted

 

Abbott

 

Divested

 

Adjusted

 

 

 

Non-GAAP

 

 

 

Reported

 

Diagnostics

 

Revenue

 

Reported

 

Businesses a)

 

Revenue

 

Reported

 

Reported

 

Organic b)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Company

 

15,157

 

(1,043

)

14,114

 

12,972

 

(187

)

12,785

 

16.8

 

10.4

 

7.5

 

U.S.

 

5,377

 

(581

)

4,796

 

4,684

 

(84

)

4,600

 

14.8

 

4.2

 

4.2

 

Int’l

 

9,780

 

(462

)

9,318

 

8,288

 

(103

)

8,185

 

18.0

 

13.8

 

9.3

 

Total Diagnostics

 

3,710

 

(1,043

)

2,667

 

2,431

 

 

2,431

 

52.6

 

9.7

 

6.1

 

U.S.

 

1,352

 

(581

)

771

 

756

 

 

756

 

78.9

 

2.0

 

2.0

 

Int’l

 

2,358

 

(462

)

1,896

 

1,675

 

 

1,675

 

40.8

 

13.2

 

7.9

 

Rapid Diagnostics

 

1,043

 

(1,043

)

 

 

 

 

n/m

 

n/m

 

n/m

 

U.S.

 

581

 

(581

)

 

 

 

 

n/m

 

n/m

 

n/m

 

Int’l

 

462

 

(462

)

 

 

 

 

n/m

 

n/m

 

n/m

 

Total Medical Devices

 

5,635

 

 

5,635

 

4,991

 

(12

)

4,979

 

12.9

 

13.2

 

8.8

 

U.S.

 

2,468

 

 

2,468

 

2,327

 

(6

)

2,321

 

6.0

 

6.3

 

6.3

 

Int’l

 

3,167

 

 

3,167

 

2,664

 

(6

)

2,658

 

18.9

 

19.1

 

11.0

 

Cardiovascular and Neuromodulation

 

4,744

 

 

4,744

 

4,363

 

(12

)

4,351

 

8.7

 

9.0

 

5.3

 

U.S.

 

2,270

 

 

2,270

 

2,171

 

(6

)

2,165

 

4.6

 

4.9

 

4.9

 

Int’l

 

2,474

 

 

2,474

 

2,192

 

(6

)

2,186

 

12.9

 

13.1

 

5.6

 

Vascular

 

1,489

 

 

1,489

 

1,434

 

(12

)

1,422

 

3.9

 

4.7

 

0.6

 

U.S.

 

570

 

 

570

 

599

 

(6

)

593

 

(4.9

)

(4.0

)

(4.0

)

Int’l

 

919

 

 

919

 

835

 

(6

)

829

 

10.2

 

10.9

 

3.9

 

 


a) Reflects sales related to the AMO and St. Jude Medical vascular closure businesses prior to divesting in the first quarter 2017.

b) In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

18



 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2018

(in millions, except per share data)

(unaudited)

 

 

 

Acquisition or
Divestiture-
related (a)

 

Restructuring
and Cost
Reduction
Initiatives (b)

 

Intangible
Amortization

 

Other (c)

 

Total
Specifieds

 

Gross Margin

 

$

37

 

$

78

 

$

562

 

$

 

$

677

 

R&D

 

(5

)

(1

)

 

(18

)

(24

)

SG&A

 

(75

)

(4

)

 

 

(79

)

Interest expense, net

 

 

 

 

(2

)

(2

)

Other (income) expense, net

 

(5

)

 

 

49

 

44

 

Earnings from Continuing Operations before taxes

 

$

122

 

$

83

 

$

562

 

$

(29

)

738

 

Tax expense on Earnings from Continuing Operations (d)

 

 

 

 

 

 

 

 

 

161

 

Earnings from Continuing Operations

 

 

 

 

 

 

 

 

 

$

577

 

Diluted Earnings per Share from Continuing Operations

 

 

 

 

 

 

 

 

 

$

0.33

 

 

The table above provides additional details regarding the specified items described on page 14.

 


a)             Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, and fair value adjustments to contingent consideration related to a business acquisition.

 

b)             Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)              Other (income) expense, net relates to an increase in fair value of an investment, partially offset by the acquisition of an R&D asset.

 

d)             Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

19



 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2017

(in millions, except per share data)

(unaudited)

 

 

 

Acquisition or
Divestiture-
related (a)

 

Restructuring
and Cost
Reduction
Initiatives (b)

 

Intangible
Amortization

 

Total
Specifieds

 

Gross Margin

 

$

438

 

$

65

 

$

392

 

$

895

 

R&D

 

(12

)

(3

)

 

(15

)

SG&A

 

(134

)

(4

)

 

(138

)

Interest expense, net

 

(2

)

 

 

(2

)

Other (income) expense, net

 

32

 

 

 

32

 

Earnings from Continuing Operations before taxes

 

$

554

 

$

72

 

$

392

 

1,018

 

Tax expense on Earnings from Continuing Operations (c)

 

 

 

 

 

 

 

192

 

Earnings from Continuing Operations

 

 

 

 

 

 

 

$

826

 

Diluted Earnings per Share from Continuing Operations

 

 

 

 

 

 

 

$

0.47

 

 

The table above provides additional details regarding the specified items described on page 14.

 


a)             Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions and integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Divestiture-related expenses include incremental costs to separate the divested businesses.

 

b)             Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. Any gains related to the divestiture of a facility as part of a restructuring program are also included in this category.

 

c)              Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

20



 

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2018

(in millions, except per share data)

(unaudited)

 

 

 

Acquisition or
Divestiture-
related (a)

 

Restructuring
and Cost
Reduction
Initiatives (b)

 

Intangible
Amortization

 

Other (c)

 

Total
Specifieds

 

Gross Margin

 

$

82

 

$

96

 

$

1,146

 

$

 

$

1,324

 

R&D

 

(21

)

(3

)

 

(43

)

(67

)

SG&A

 

(161

)

(8

)

 

 

(169

)

Interest expense, net

 

 

 

 

(2

)

(2

)

Net foreign exchange (gain) loss

 

 

(1

)

 

 

(1

)

Debt extinguishment costs

 

 

 

 

(14

)

(14

)

Other (income) expense, net

 

(7

)

 

 

49

 

42

 

Earnings from Continuing Operations before taxes

 

$

271

 

$

108

 

$

1,146

 

$

10

 

1,535

 

Tax expense on Earnings from Continuing Operations (d)

 

 

 

 

 

 

 

 

 

317

 

Earnings from Continuing Operations

 

 

 

 

 

 

 

 

 

$

1,218

 

Diluted Earnings per Share from Continuing Operations

 

 

 

 

 

 

 

 

 

$

0.69

 

 

The table above provides additional details regarding the specified items described on page 15.

 


a)             Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization.

 

b)             Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)              Other (income) expense, net relates to the acquisition of R&D assets and the cost associated with the early extinguishment of debt, partially offset by an increase in fair value of an investment.

 

d)             Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

21



 

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2017

(in millions, except per share data)

(unaudited)

 

 

 

Acquisition or
Divestiture-
related (a)

 

Restructuring
and Cost
Reduction
Initiatives (b)

 

Intangible
Amortization

 

Total
Specifieds

 

Gross Margin

 

$

844

 

$

121

 

$

914

 

$

1,879

 

R&D

 

(26

)

(29

)

 

(55

)

SG&A

 

(486

)

(19

)

 

(505

)

Interest expense, net

 

(19

)

 

 

(19

)

Other (income) expense, net

 

1,200

 

(34

)

 

1,166

 

Earnings from Continuing Operations before taxes

 

$

175

 

$

203

 

$

914

 

1,292

 

Tax expense on Earnings from Continuing Operations (c)

 

 

 

 

 

 

 

9

 

Earnings from Continuing Operations

 

 

 

 

 

 

 

$

1,283

 

Diluted Earnings per Share from Continuing Operations

 

 

 

 

 

 

 

$

0.74

 

 

The table above provides additional details regarding the specified items described on page 15.

 


a)             Acquisition-related expenses include bankers’ fees and costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. The specified items in interest expense include amortization expense associated with acquisition-related bridge facility fees. Divestiture-related expenses include incremental costs to separate the divested businesses as well as bankers’ fees and costs for legal, accounting, tax, and other services related to the divestitures.

 

b)             Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. Any gains related to the divestiture of a facility as part of a restructuring program are also included in this category.

 

c)              Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

###

 

22